Fibroblast growth factor receptor 2 inhibitors were the first to transform the clinical management of ICC, displaying the required efficacy in fusion-positive cases; however, those cases account for only 10–20% of the total [6], similar to cases with mutations in isocitrate dehydrogenase (IDH) [7]. The gene discussed is IDH1; the disease is intrahepatic cholangiocarcinoma.